A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder
Terminated · Phase 1 · NCT06618118
Conditions: Major Depressive Disorder (MDD)
At a glance
- Research payments reported, 2025
- $927,392
- U.S. investigators named
- 6
- Sites paid
- 10
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- AbbVie
- Tested
- Fosigotifator (drug), Placebo (drug)
- Dates
- Started 2024-10-23; completion 2025-09-23
- Results posted
- Not yet
Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains. The main goal of the study is to evaluate how safe and effective fosigotifator is in treating MDD. Fosigotifator (ABBV-CLS-7262) is a new treatment being developed for adult patients with depression. This study is double-blinded, which means that neither the patients nor the study doctors know who is given fosigotifator and who is given pla…
From ClinicalTrials.gov, last updated 2025-09-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $927,392 in research payments for this study in 2025 (69 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Pamela L. Alvarez, M.D. Neurology · Murrieta, CA
- Iman Parhami, M.D., MPH Psychiatry · Woodland Hills, CA
- Kimball A. Johnson, MD Internal Medicine · Atlanta, GA
- Felipe P. Suplicy, M.D. Psychiatry · Rome, GA
- Kurian C. Abraham, MD Psychiatry · Charlotte, NC
- Arun Arora, M.D. Psychiatry · Bellevue, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- California Neuroscience $333,329
- Northwest Clinical Research Ctr $268,561
- Clinical Neuroscience Solutions in $220,213
- Cenexel Iresearch LLC $63,213
- New Hope Clinical Research Inc $10,062
- Cenexel Iresearch Atlanta $7,861
- Clinical Neuroscience Solutions Inc $7,861
- Northwest Clinical Research Center $7,146
- California Neuroscience Research Medical Group Inc $7,146
- Viking Pharmaceutical Trials Inc $2,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.